{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:26:42Z","timestamp":1781663202512,"version":"3.54.5"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5R01HL114567"],"award-info":[{"award-number":["5R01HL114567"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32HL007062"],"award-info":[{"award-number":["T32HL007062"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","translationalres.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.trsl.2022.06.018","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T20:51:12Z","timestamp":1658523072000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["MASP-2 and MASP-3 inhibitors block complement activation, inflammation, and microvascular stasis in a murine model of vaso-occlusion in sickle cell disease"],"prefix":"10.1016","volume":"249","author":[{"given":"John D.","family":"Belcher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunsheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuad","family":"Abdulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruan","family":"Conglin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zalaya K.","family":"Ivy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Dudler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M.","family":"Vercellotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trsl.2022.06.018_bib0001","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1172\/JCI133639","article-title":"The multifaceted role of ischemia\/reperfusion in sickle cell anemia","volume":"130","author":"Hebbel","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2022.06.018_bib0002","first-page":"77","article-title":"Serum complement activity in normal individuals and patients with sickle cell hemoglobin abnormalities","volume":"33","author":"Francis","year":"1967","journal-title":"Am J Med Technol"},{"key":"10.1016\/j.trsl.2022.06.018_bib0003","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.3324\/haematol.2017.174201","article-title":"In vitro evidence of complement activation in patients with sickle cell disease","volume":"102","author":"Gavriilaki","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.trsl.2022.06.018_bib0004","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3324\/haematol.2018.198622","article-title":"Factor H interferes with the adhesion of sickle red cells to vascular endothelium: a novel disease-modulating molecule","volume":"104","author":"Lombardi","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.trsl.2022.06.018_bib0005","doi-asserted-by":"crossref","first-page":"e96910","DOI":"10.1172\/jci.insight.96910","article-title":"Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles","volume":"3","author":"Merle","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.trsl.2022.06.018_bib0006","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/ajh.25742","article-title":"Complement activation in sickle cell disease: dependence on cell density, hemolysis and modulation by hydroxyurea therapy","volume":"95","author":"Roumenina","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.trsl.2022.06.018_bib0007","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1182\/blood-2021-154132","article-title":"Complement activation during vaso-occlusive pain crisis in pediatric sickle cell disease","volume":"138","author":"Yoo","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2022.06.018_bib0008","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ajh.25384","article-title":"Critical role of C5a in sickle cell disease","volume":"94","author":"Vercellotti","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.trsl.2022.06.018_bib0009","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1055\/s-0038-1672189","article-title":"Complement component C3 binds to the A3 domain of von Willebrand factor","volume":"2","author":"Nolasco","year":"2018","journal-title":"TH Open: Companion J Thrombos Haemost"},{"key":"10.1016\/j.trsl.2022.06.018_bib0010","doi-asserted-by":"crossref","first-page":"6280","DOI":"10.1073\/pnas.1814797116","article-title":"P-selectin drives complement attack on endothelium during intravascular hemolysis in TLR-4\/heme-dependent manner","volume":"116","author":"Merle","year":"2019","journal-title":"Proc Nat Acad Sci USA"},{"key":"10.1016\/j.trsl.2022.06.018_bib0011","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1002\/j.2040-4603.2021.tb00164.x","article-title":"Vasculopathy in sickle cell disease: from red blood cell sickling to vascular dysfunction","volume":"11","author":"Nader","year":"2021","journal-title":"Compr Physiol"},{"key":"10.1016\/j.trsl.2022.06.018_bib0012","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/ajh.21475","article-title":"Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions","volume":"84","author":"Kato","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.trsl.2022.06.018_bib0013","first-page":"H1211","article-title":"Myocyte and endothelial injury with ischemia reperfusion in isolated rat hearts","volume":"252","author":"Sunnergren","year":"1987","journal-title":"Am J Physiol"},{"key":"10.1016\/j.trsl.2022.06.018_bib0014","first-page":"191","article-title":"Pulmonary edema: ischemia reperfusion endothelial injury and its reversal by c-AMP","volume":"15","author":"Taylor","year":"1991","journal-title":"Proc Natl Sci Counc Repub China B"},{"key":"10.1016\/j.trsl.2022.06.018_bib0015","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.brainres.2009.07.054","article-title":"Elevation of jugular venous superoxide anion radical is associated with early inflammation, oxidative stress, and endothelial injury in forebrain ischemia-reperfusion rats","volume":"1292","author":"Aki","year":"2009","journal-title":"Brain Res"},{"key":"10.1016\/j.trsl.2022.06.018_bib0016","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1172\/JCI89741","article-title":"Intravascular hemolysis and the pathophysiology of sickle cell disease","volume":"127","author":"Kato","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2022.06.018_bib0017","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40164-021-00249-8","article-title":"Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy","volume":"10","author":"Gavriilaki","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.trsl.2022.06.018_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.742446","article-title":"Complement alternative and mannose-binding lectin pathway activation is associated with COVID-19 mortality","volume":"12","author":"Defendi","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.trsl.2022.06.018_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.714511","article-title":"Lectin pathway mediates complement activation by SARS-CoV-2 proteins","volume":"12","author":"Ali","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.trsl.2022.06.018_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2020.152001","article-title":"Endothelial injury and thrombotic microangiopathy in COVID-19: treatment with the lectin-pathway inhibitor narsoplimab","volume":"225","author":"Rambaldi","year":"2020","journal-title":"Immunobiology"},{"key":"10.1016\/j.trsl.2022.06.018_bib0021","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/jth.13208","article-title":"The lectin complement pathway serine proteases (MASPs) represent a possible crossroad between the coagulation and complement systems in thromboinflammation","volume":"14","author":"Kozarcanin","year":"2016","journal-title":"J Thrombos Haemost JTH"},{"key":"10.1016\/j.trsl.2022.06.018_bib0022","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1365-2567.2009.03200.x","article-title":"Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot","volume":"129","author":"Gulla","year":"2010","journal-title":"Immunology"},{"key":"10.1016\/j.trsl.2022.06.018_bib0023","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0002-9440(10)63424-4","article-title":"The mannose-binding lectin-pathway is involved in complement activation in the course of renal ischemia-reperfusion injury","volume":"165","author":"de Vries","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1016\/j.trsl.2022.06.018_bib0024","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3389\/fimmu.2012.00341","article-title":"Sacks SH. Which pathways trigger the role of complement in ischaemia\/reperfusion injury?","volume":"3","author":"Farrar","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.trsl.2022.06.018_bib0025","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1161\/hc3601.095578","article-title":"Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury","volume":"104","author":"Jordan","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.trsl.2022.06.018_bib0026","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1177\/1479164109336051","article-title":"The mannose-binding lectin pathway is a significant contributor to reperfusion injury in the type 2 diabetic heart","volume":"6","author":"La Bonte","year":"2009","journal-title":"Diabetes Vasc Dis Res"},{"key":"10.1016\/j.trsl.2022.06.018_bib0027","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12974-016-0684-6","article-title":"Mannan binding lectin-associated serine protease-2 (MASP-2) critically contributes to post-ischemic brain injury independent of MASP-1","volume":"13","author":"Orsini","year":"2016","journal-title":"J Neuroinflamm"},{"key":"10.1016\/j.trsl.2022.06.018_bib0028","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.3389\/fimmu.2018.01151","article-title":"The lectin pathway of complement in myocardial ischemia\/reperfusion injury-review of its significance and the potential impact of therapeutic interference by C1 esterase inhibitor","volume":"9","author":"Panagiotou","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.trsl.2022.06.018_bib0029","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s12035-018-1066-0","article-title":"Changes in the lectin pathway following intracerebral or spontaneous subarachnoid hemorrhage","volume":"56","author":"Sandgaard","year":"2019","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.trsl.2022.06.018_bib0030","doi-asserted-by":"crossref","first-page":"7523","DOI":"10.1073\/pnas.1101748108","article-title":"Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia\/reperfusion injury","volume":"108","author":"Schwaeble","year":"2011","journal-title":"Proc Nat Acad Sci USA"},{"key":"10.1016\/j.trsl.2022.06.018_bib0031","doi-asserted-by":"crossref","first-page":"13445","DOI":"10.1073\/pnas.1406849111","article-title":"Complement activation by ligand-driven juxtaposition of discrete pattern recognition complexes","volume":"111","author":"Degn","year":"2014","journal-title":"Proc Nat Acad Sci USA"},{"key":"10.1016\/j.trsl.2022.06.018_bib0032","doi-asserted-by":"crossref","first-page":"857","DOI":"10.4049\/jimmunol.1501717","article-title":"MASP-1 and MASP-2 do not activate pro-factor D in resting human blood, whereas MASP-3 is a potential activator: kinetic analysis involving specific MASP-1 and MASP-2 inhibitors","volume":"196","author":"Oroszl\u00e1n","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.trsl.2022.06.018_bib0033","doi-asserted-by":"crossref","first-page":"31877","DOI":"10.1038\/srep31877","article-title":"MASP-3 is the exclusive pro-factor D activator in resting blood: the lectin and the alternative complement pathways are fundamentally linked","volume":"6","author":"Dob\u00f3","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.trsl.2022.06.018_bib0034","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.4049\/jimmunol.1900605","article-title":"Cutting edge: role of MASP-3 in the physiological activation of factor D of the alternative complement pathway","volume":"203","author":"Hayashi","year":"2019","journal-title":"J Immunol"},{"key":"10.1016\/j.trsl.2022.06.018_bib0035","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/978-1-4614-4118-2_3","article-title":"The role of MASP-1\/3 in complement activation","volume":"735","author":"Sekine","year":"2013","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.trsl.2022.06.018_bib0036","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJM199107043250103","article-title":"Pain in sickle cell disease. Rates and risk factors","volume":"325","author":"Platt","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2022.06.018_bib0037","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2006-02-004812","article-title":"Correction of sickle cell disease by homologous recombination in embryonic stem cells","volume":"108","author":"Wu","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2022.06.018_bib0038","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/ajh.20143","article-title":"Microvascular blood flow and stasis in transgenic sickle mice: utility of a dorsal skin fold chamber for intravital microscopy","volume":"77","author":"Kalambur","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1016\/j.trsl.2022.06.018_bib0039","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00109-010-0613-6","article-title":"Heme oxygenase-1 gene delivery by sleeping beauty inhibits vascular stasis in a murine model of sickle cell disease","volume":"88","author":"Belcher","year":"2010","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.trsl.2022.06.018_bib0040","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/archdischild-2020-319778","article-title":"Clinical management of sickle cell liver disease in children and young adults","volume":"106","author":"Kyrana","year":"2021","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.trsl.2022.06.018_bib0041","first-page":"31","article-title":"Nuclear factor-kappaB: activation and regulation during toll-like receptor signaling","volume":"4","author":"Carmody","year":"2007","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.trsl.2022.06.018_bib0042","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood-2013-03-489245","article-title":"Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome","volume":"122","author":"Frimat","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2022.06.018_bib0043","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1194\/jlr.M600094-JLR200","article-title":"High density lipoprotein subfractions: isolation, composition, and their duplicitous role in oxidation","volume":"48","author":"McPherson","year":"2007","journal-title":"J Lipid Res"},{"key":"10.1016\/j.trsl.2022.06.018_bib0044","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1096\/fj.13-246306","article-title":"Mannan-binding lectin-associated serine protease 2 is critical for the development of renal ischemia reperfusion injury and mediates tissue injury in the absence of complement C4","volume":"28","author":"Asgari","year":"2014","journal-title":"FASEB J"},{"key":"10.1016\/j.trsl.2022.06.018_bib0045","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1182\/blood-2013-04-495887","article-title":"Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease","volume":"123","author":"Belcher","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2022.06.018_bib0046","doi-asserted-by":"crossref","first-page":"6408","DOI":"10.3390\/ijms22126408","article-title":"Critical role of hemopexin mediated cytoprotection in the pathophysiology of sickle cell disease","volume":"22","author":"Ashouri","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.trsl.2022.06.018_bib0047","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196455","article-title":"Haptoglobin and hemopexin inhibit vaso-occlusion and inflammation in murine sickle cell disease: role of heme oxygenase-1 induction","volume":"13","author":"Belcher","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2022.06.018_bib0048","doi-asserted-by":"crossref","first-page":"561917","DOI":"10.3389\/fimmu.2020.561917","article-title":"The worst things in life are free: the role of free heme in sickle cell disease","volume":"11","author":"Gbotosho","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.trsl.2022.06.018_bib0049","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.4049\/jimmunol.2000636","article-title":"Proprotein convertase is the highest-level activator of the alternative complement pathway in the blood","volume":"206","author":"Oroszl\u00e1n","year":"2021","journal-title":"J Immunol"},{"key":"10.1016\/j.trsl.2022.06.018_bib0050","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/imr.12468","article-title":"A journey through the lectin pathway of complement-MBL and beyond","volume":"274","author":"Garred","year":"2016","journal-title":"Immunol Rev"},{"key":"10.1016\/j.trsl.2022.06.018_bib0051","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2020.04.007","article-title":"Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases","volume":"220","author":"Magro","year":"2020","journal-title":"Transl Res"},{"key":"10.1016\/j.trsl.2022.06.018_bib0052","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3390\/v13020312","article-title":"Targeting the complement serine protease MASP-2 as a therapeutic strategy for coronavirus infections","volume":"13","author":"Flude","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.trsl.2022.06.018_bib0053","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.ekir.2020.08.003","article-title":"Tolerability and efficacy of narsoplimab, a novel MASP-2 inhibitor for the treatment of IgA nephropathy","volume":"5","author":"Lafayette","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.trsl.2022.06.018_bib0054","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s40478-020-01041-1","article-title":"Targeted deletions of complement lectin pathway genes improve outcome in traumatic brain injury, with MASP-2 playing a major role","volume":"8","author":"Mercurio","year":"2020","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.trsl.2022.06.018_bib0055","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2017-000652","article-title":"Cardioprotection by an anti-MASP-2 antibody in a murine model of myocardial infarction","volume":"5","author":"Clark","year":"2018","journal-title":"Open Heart"},{"key":"10.1016\/j.trsl.2022.06.018_bib0056","article-title":"Endothelial TLR4 expression mediates vaso-occlusive crisis in sickle cell disease","volume":"11","author":"Beckman","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.trsl.2022.06.018_bib0057","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1182\/blood-2002-10-3313","article-title":"Transgenic sickle mice have vascular inflammation","volume":"101","author":"Belcher","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2022.06.018_bib0058","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1089\/ars.2015.6571","article-title":"Control of oxidative stress and inflammation in sickle cell disease with the Nrf2 activator dimethyl fumarate","volume":"26","author":"Belcher","year":"2017","journal-title":"Antioxid Redox Signaling"},{"key":"10.1016\/j.trsl.2022.06.018_bib0059","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1172\/JCI26857","article-title":"Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice","volume":"116","author":"Belcher","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2022.06.018_bib0060","doi-asserted-by":"crossref","first-page":"H2715","DOI":"10.1152\/ajpheart.00986.2004","article-title":"Critical role of endothelial cell activation in hypoxia-induced vasoocclusion in transgenic sickle mice","volume":"288","author":"Belcher","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.trsl.2022.06.018_bib0061","article-title":"Vasculotoxic and pro-inflammatory effects of plasma heme: cell signaling and cytoprotective responses","volume":"2013","author":"Belcher","year":"2013","journal-title":"ISRN Oxid Med"},{"key":"10.1016\/j.trsl.2022.06.018_bib0062","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/03630269.2018.1540353","article-title":"Successful outcome of hyperhemolysis in sickle cell disease following multiple lines of treatment: the role of complement inhibition","volume":"42","author":"Vlachaki","year":"2018","journal-title":"Hemoglobin"},{"key":"10.1016\/j.trsl.2022.06.018_bib0063","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2147\/JBM.S287301","article-title":"Complement in sickle cell disease: are we ready for prime time?","volume":"12","author":"Varelas","year":"2021","journal-title":"J Blood Med"},{"key":"10.1016\/j.trsl.2022.06.018_bib0064","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.3324\/haematol.2020.262006","article-title":"Eculizumab for complement mediated thrombotic microangiopathy in sickle cell disease","volume":"105","author":"Chonat","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.trsl.2022.06.018_bib0065","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3324\/haematol.2019.224709","article-title":"Hemolytic transfusion reactions in sickle cell disease: underappreciated and potentially fatal","volume":"105","author":"Thein","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.trsl.2022.06.018_bib0066","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/MOH.0000000000000610","article-title":"Role of complement in alloimmunization and hyperhemolysis","volume":"27","author":"Chonat","year":"2020","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.trsl.2022.06.018_bib0067","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1182\/bloodadvances.2019001143","article-title":"American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support","volume":"4","author":"Chou","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.trsl.2022.06.018_bib0068","doi-asserted-by":"crossref","first-page":"18","DOI":"10.14740\/jh553","article-title":"Delayed hemolytic transfusion reaction in a patient with sickle cell disease and the role of the classical complement pathway: a case report","volume":"10","author":"Hair","year":"2021","journal-title":"J Hematol"},{"key":"10.1016\/j.trsl.2022.06.018_bib0069","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1182\/blood-2021-147854","article-title":"Trial in progress: the randomized, double-blind, placebo-controlled phase Ib CROSSWALK-a trial evaluating the safety of crovalimab for the management of acute uncomplicated vaso-occlusive episodes (VOEs) in patients with sickle cell disease (SCD)","volume":"138","author":"Bartolucci","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2022.06.018_bib0070","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1182\/blood-2021-151222","article-title":"Trial in progress: the randomized, double-blind, placebo-controlled phase IIa CROSSWALK-c trial evaluating the efficacy of crovalimab as adjunct treatment in the prevention of vaso-occlusive episodes (VOEs) in patients with sickle cell disease (SCD)","volume":"138","author":"Callaghan","year":"2021","journal-title":"Blood"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524422001529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524422001529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T12:45:50Z","timestamp":1761828350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524422001529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":70,"alternative-id":["S1931524422001529"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2022.06.018","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MASP-2 and MASP-3 inhibitors block complement activation, inflammation, and microvascular stasis in a murine model of vaso-occlusion in sickle cell disease","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2022.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}